|
Jul 11
|
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
|
|
Jul 11
|
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List
|
|
Jul 10
|
Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders
|
|
Jul 9
|
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
|
|
Jul 8
|
Teva’s Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial
|
|
Jul 7
|
Teva Recognized Among TIME and Statista's 2025 World's Most Sustainable Companies
|
|
Jul 7
|
Deckers Outdoor Corporation's Quarterly Earnings Preview: What You Need to Know
|
|
Jul 1
|
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen solid returns of 112% over the past three years
|
|
Jun 26
|
Teva Releases Q2 2025 Aide Memoire
|
|
Jun 25
|
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
|
|
Jun 25
|
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
|
|
Jun 24
|
Teva reports final analysis of migraine prevention trial of Ajovy
|
|
Jun 24
|
Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth
|
|
Jun 23
|
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
|
|
Jun 23
|
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
|
|
Jun 10
|
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
|
|
Jun 9
|
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
|
|
May 15
|
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
|
|
May 15
|
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
|
|
May 15
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|